Patents by Inventor Dalton James Surmeier, JR.

Dalton James Surmeier, JR. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dihydropyridine compositions and methods for treating neurological disorders
    Patent number: 11850243
    Abstract: The present disclosure provides extended or sustained release compositions of a dihydropyridine calcium channel blocker, specifically isradipine, and method of using the compositions for the treatment of neurological disorders, wherein the composition provides sustained plasma levels of the dihydropyridine calcium channel blocker.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: December 26, 2023
    Assignees: Northwestern University, Cavalon Therapeutics, Inc.
    Inventors: Jack Nguyen, Dalton James Surmeier, Jr.
  • Compositions and methods to reduce pharmaceutical-induced toxicity
    Patent number: 11554103
    Abstract: Provided herein are compositions and methods to reduce toxicity resulting from pharmaceutical treatment, that can lead to increased risk of developing Parkinson's disease (PD) and/or acceleration of PD-associated deterioration.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: January 17, 2023
    Assignee: Northwestern University
    Inventors: Dalton James Surmeier, Jr., Steven M. Graves
  • DIHYDROPYRIDINE COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS
    Publication number: 20220241262
    Abstract: The present disclosure provides extended or sustained release compositions of a dihydropyridine calcium channel blocker, specifically isradipine, and method of using said compositions for the treatment of neurological disorders, wherein the composition provides sustained plasma levels of the dihydropyridine calcium channel blocker.
    Type: Application
    Filed: January 12, 2022
    Publication date: August 4, 2022
    Inventors: Jack NGUYEN, Dalton James SURMEIER, JR.
  • Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias
    Patent number: 11246871
    Abstract: Provided herein are compositions and methods for the treatment and of neurodegenerative disorders and levodopa-induced dyskinesias. In particular, A2a receptor antagonists are provided, as well as methods for the use of A2a receptor antagonists in the treatment of neurodegenerative disorders (e.g., Parkinsons disease) and the treatment and/or prevention levodopa-induced dyskinesias associated with such treatment.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: February 15, 2022
    Assignee: Northwestern University
    Inventors: Dalton James Surmeier, Jr., Weixing Shen
  • TARGETING ADENOSINE A2A RECEPTORS FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIAS
    Publication number: 20200316074
    Abstract: Provided herein are compositions and methods for the treatment and of neurodegenerative disorders and levodopa-induced dyskinesias. In particular, A2a receptor antagonists are provided, as well as methods for the use of A2a receptor antagonists in the treatment of neurodegenerative disorders (e.g., Parkinsons disease) and the treatment and/or prevention levodopa-induced dyskinesias associated with such treatment.
    Type: Application
    Filed: July 14, 2017
    Publication date: October 8, 2020
    Inventors: Dalton James Surmeier, Jr., Weixing Shen
  • COMPOSITIONS AND METHODS TO REDUCE PHARMACEUTICAL-INDUCED TOXICITY
    Publication number: 20180153839
    Abstract: Provided herein are compositions and methods to reduce toxicity resulting from pharmaceutical treatment, that can lead to increased risk of developing Parkinson's disease (PD) and/or acceleration of PD-associated deterioration.
    Type: Application
    Filed: November 10, 2017
    Publication date: June 7, 2018
    Inventors: Dalton James Surmeier, JR., Steven M. Graves